Integrated Filing — IndAS



General information about company

Scrip Code 532331
NSE Symbol AJANTPHARM
MSEI Symbol NA
ISIN INE031B01049
Name of company AJANTA PHARMA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 30-07-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 20-07-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Pharmaceutical
Start date and time of board meeting 30-07-2026   13:30:00
End date and time of board meeting 30-07-2026   14:28:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 1,62,596.00 1,62,596.00
Other income 7,090.00 7,090.00
Total income 1,69,686.00 1,69,686.00
2 Expenses
(a) Cost of materials consumed 29,651.00 29,651.00
(b) Purchases of stock-in-trade 6,692.00 6,692.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (3,558.00) (3,558.00)
(d) Employee benefit expense 38,111.00 38,111.00
(e) Finance costs 318.00 318.00
(f) Depreciation, depletion and amortisation expense 4,450.00 4,450.00
(f) Other Expenses
1 Other expenses 49,342.00 49,342.00
Total other expenses 49,342.00 49,342.00
Total expenses 1,25,006.00 1,25,006.00
3 Total profit before exceptional items and tax 44,680.00 44,680.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 44,680.00 44,680.00
6 Tax expense
7 Current tax 10,272.00 10,272.00
8 Deferred tax 986.00 986.00
9 Total tax expenses 11,258.00 11,258.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 33,422.00 33,422.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 33,422.00 33,422.00
17 Other comprehensive income net of taxes (426.00) (426.00)
18 Total Comprehensive Income for the period 32,996.00 32,996.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 32,996.00 32,996.00
Total profit or loss, attributable to non-controlling interests 0.00 0.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 32,996.00 32,996.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0.00 0.00
21 Details of equity share capital
Paid-up equity share capital 2,507.00 2,507.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 26.75 26.75
Diluted earnings (loss) per share from continuing operations 26.72 26.72
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 26.75 26.75
Diluted earnings (loss) per share from continuing and discontinued operations 26.72 26.72
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes : 1. The above consolidated financial results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 30 July 2026. The statutory auditors have expressed an unmodified conclusion. The review report has been filed with the stock exchange and is available on company website. The consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards ('Ind AS') as prescribed under Section 133 of the Companies Act, 2013 (the Act) read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2. The consolidated unaudited financial results of the Company, its wholly owned subsidiaries (“the Group”) have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest. 3. The figures for the quarter ended 31 March 2026 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figure upto the third quarter ended 31 December 2025. 4. Board of Directors have approved 1st interim dividend of Rs. 399.79 Crore for financial year 2026-27 to its shareholders@ Rs. 32 per share on the face value of Rs. 2 per share. 5. Other income / Other expense includes : 3 months ended Year Ended Rs. in Crore 30-Jun-26 31-Mar-26 30-Jun-25 31-Mar-26 Foreign exchange gain (in other income) 50.47 44.37 9.38 97.17 Foreign exchange loss (in other expense) 30.59 41.70 25.15 103.04 6. In August 2025, the Income Tax Authorities carried out search operations and the Company filed the return for the block period from 1 April 2019 to 17 November 2025 on 6 April 2026. Pending any subsequent communication from the concerned authorities in this regard, the consequent impact on the consolidated financial results for the quarter ended 30 June 2026, if any, is currently not ascertainable. 7. The Group operates exclusively in one reportable business segment i.e., Pharmaceuticals. 8. The Financial Results are available on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026 01-04-2026
Date of end of reporting period 30-06-2026 30-06-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified subsequently to profit or loss (511.00) (511.00)
Total Amount of items that will not be reclassified to profit and loss (511.00)
2 Income tax relating to items that will not be reclassified to profit or loss (179.00) (179.00)
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified subsequently to profit or loss (94.00) (94.00)
Total Amount of items that will be reclassified to profit and loss (94.00)
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (426.00) (426.00)